184 related articles for article (PubMed ID: 19095414)
1. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany.
Alba V; Urban E; Angeles Dominguez M; Nagy E; Nord CE; Palacín C; Vila J
Int J Antimicrob Agents; 2009 Mar; 33(3):272-5. PubMed ID: 19095414
[TBL] [Abstract][Full Text] [Related]
2. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections.
Nenoff P; Haustein UF; Hittel N
Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398
[TBL] [Abstract][Full Text] [Related]
3. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
Kuwahara K; Kitazawa T; Kitagaki H; Tsukamoto T; Kikuchi M
J Dermatol Sci; 2005 Apr; 38(1):47-55. PubMed ID: 15795123
[TBL] [Abstract][Full Text] [Related]
4. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
Komagata Y; Komiyama K; Nomura S
Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
6. [Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections].
Matsuzaki K; Omika K; Hasegawa M; Sato Y; Kobayashi I
Jpn J Antibiot; 2006 Aug; 59(4):316-20. PubMed ID: 17111596
[TBL] [Abstract][Full Text] [Related]
7. Bacteriologic profile of the conjunctiva in the patients with dry eye.
Hori Y; Maeda N; Sakamoto M; Koh S; Inoue T; Tano Y
Am J Ophthalmol; 2008 Nov; 146(5):729-34. PubMed ID: 18672220
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne.
Gübelin W; Martínez MA; Molina MT; Zapata S; Valenzuela ME
Rev Latinoam Microbiol; 2006; 48(1):14-6. PubMed ID: 17357569
[TBL] [Abstract][Full Text] [Related]
9. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes.
Oprica C; Nord CE;
Clin Microbiol Infect; 2005 Mar; 11(3):204-13. PubMed ID: 15715718
[TBL] [Abstract][Full Text] [Related]
10. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions.
Nishijima S; Kurokawa I; Katoh N; Watanabe K
J Dermatol; 2000 May; 27(5):318-23. PubMed ID: 10875198
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris.
Vogt K; Hermann J; Blume U; Gollnick H; Hahn H; Haustein UF; Orfanos CE
Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):943-5. PubMed ID: 1486893
[TBL] [Abstract][Full Text] [Related]
12. Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes.
Nakase K; Nakaminami H; Toda Y; Noguchi N
Chemotherapy; 2017; 62(2):94-99. PubMed ID: 27764829
[TBL] [Abstract][Full Text] [Related]
13. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris.
Kurokawa I; Nishijima S; Kawabata S
Eur J Dermatol; 1999; 9(1):25-8. PubMed ID: 9920982
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
Zhang Y; Li G; Liu M; You X; Feng L; Lv K; Cao J; Guo H
Bioorg Med Chem Lett; 2011 Feb; 21(3):928-31. PubMed ID: 21232952
[TBL] [Abstract][Full Text] [Related]
17. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream.
Plewig G; Holland KT; Nenoff P
Eur J Dermatol; 2006; 16(1):48-55. PubMed ID: 16436342
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris.
Vogt K; Hahn H; Hermann J; Haustein UF; Blume U; Gollnick H; Orfanos CE
Drugs; 1995; 49 Suppl 2():266-8. PubMed ID: 8549327
[No Abstract] [Full Text] [Related]
19. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A
Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment.
Kumar A; Agarwal SP; Ahuja A; Ali J; Choudhry R; Baboota S
Pharmazie; 2011 Feb; 66(2):111-4. PubMed ID: 21434572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
